Anti CD44 antibodies for eradicating stem cells
AssigneesInstitut National De La Sante Et De La Recherche Medicale (Inserm), University Health Network
InventorsFlorence Smadja, John Dick
Life of this patent
Estimating the term…
Abstract
The present invention provides the use of an anti-CD44 antibody, a (Fab′)2, Fab, Fab′ fragment thereof, an IgG or IgM isotype thereof, in the preparation of a medicament for eradicating pathological stem cells in cancer therapy, and more specifically in acute myeloid leukaemia therapy.
Claims14
A method for eradicating pathological stem cells comprising administering to a patient a pathological stem cell eradicating-effective amount of a composition comprising an anti-CD44 antibody, or a (Fab′)2, Fab, or Fab′ fragment thereof, or an IgG or IgM isotype thereof, wherein said pathological stem cells are leukaemic cells or cancer cells.
Dependencies are inferred from the claim text.